Video
Author(s):
Gemtesa (vibegron; Urovant Sciences) tablets are approved to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Gemtesa (vibegron; Urovant Sciences) tablets are indicated to treat overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency.
OAB results from the involuntary contraction of the detrusor. Symptoms can include a sudden urge to urinate that is difficult to control, unintentional loss of urine immediately after an urgent need to urinate, urinating 8 or more times in 24 hours, and waking more than twice nightly to urinate.
OAB affects more than 30 million adults in the United States and often significantly affects daily activities.